Pallas Pharma Needs 16% Out of the Cost Base
Pallas Pharma is a specialty pharma business in US turning over $1420 M. Its operating margin sits 8 points below the peer median, and the board has mandated a 16% reduction in the cost base within eighteen months.
The cost base breaks down roughly as: cost of goods 54% of revenue, people 19%, marketing 10%, technology 6%, other overhead 7%.
The last two cost programmes each announced double-digit savings and neither showed up in the margin. Headcount has grown 40% in three years while revenue grew 25%.
target
- cost reduction pct
- 16
context
- prior programmes
- 2
- revenue growth 3y pct
- 25
- headcount growth 3y pct
- 40
- margin gap to peers pts
- 8
- prior programmes visible in margin
- false
cost base pct of revenue
- cogs
- 54
- people
- 19
- marketing
- 10
- technology
- 6
- other overhead
- 7
Advise the CEO. Your answer should provide:
- Analysis — where the money actually is, and what a realistic reduction looks like by category.
- Risks — which cuts damage the business and which do not.
- Recommendation — a phased programme with amounts and a sequence.
State any assumptions you make.
80 points, 60% to pass.
- recommendation20
- market analysis15
- risk assessment20
- financial analysis25
Reveal suggested structure
Size each category in currency, apply category-specific realistic reduction rates, separate structural from discretionary, and phase by speed and reversibility.